表紙
市場調査レポート

世界のAPI市場の将来予測

Global API Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 276777
出版日 ページ情報 英文 85 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
世界のAPI市場の将来予測 Global API Market Outlook 2020
出版日: 2015年09月01日 ページ情報: 英文 85 Pages
概要

世界のAPI(Active Pharmaceutical Ingredient:医薬品原料)市場は、近年成長率が著しく、2014年〜2020年のCAGRでは約6.5%の成長が期待されています。

当レポートでは、世界のAPI市場について調査分析し、産業の実績、国別比較分析、治療セグメント別分析を提供し、新興の機会や規制環境、主要企業プロファイルなども含めてお届けいたします。

第1章 アナリストの見解

第2章 調査手法

第3章 API:概要

第4章 世界のAPI産業

第5章 市場成長促進要因と抑制因子

  • 成長促進要因
    • 高齢者人口の増加
    • 慢性疾患患者数の増加
    • 特許期間満了によるジェネリック薬用API向け市場の開放
    • アジア市場のもつ大きな成長の可能性
  • 抑制因子
    • 価格の上昇によるブランド医薬品市場の後退
    • ますます厳しくなる規制環境
    • 製品承認プロセスの期間
    • サプラーチェーンの透明性の欠如
  • 第6章 市場区分
  • 製造方法別
    • 専属市場
    • 商業市場
  • 薬の種類別
    • ジェネリック薬用API
    • ブランド薬用API
  • APIの種類
    • 商業的/小分子API
    • バイオテックAPI
  • 主要地域市場
    • 北米
    • アジア太平洋地域
    • 欧州
    • その他の地域
  • 治療分野
    • 循環器疾患
    • 糖尿病
    • 中枢神経系疾患
    • 腫瘍
    • その他

第7章 産業動向

  • 溶解性を高めるAPIのナノ結晶
  • API生産を支える技術進歩

第8章 競合情勢

  • BASF SE
  • 協和発酵キリン
  • North China Pharmaceutical Group Corporation
  • Teva Active Pharmaceutical Ingredients
  • Lonza
  • Dr Reddy's Laboratories
  • Aurobindo Pharma Limited
  • Pfizer
  • Divis Laboratories Limited
  • Royal DSM
  • Boehringer Ingelheim GmbH

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The global API market has been garnering a lot of attention since the last few years. In our report “Global API Market Outlook 2020”, the growth of the global API market has been forecasted by looking at the current market trends. This market is expected to grow at a CAGR of 6.5% from 2014-2020. The market has been segmented by type of manufacturing, type of drug, type of API and by therapeutic segment; and each segment's market has also been forecasted.

The market has been divided into four major geographies which comprise of North America, Asia Pacific, Europe and the Rest of the World. For every region, the current and future outlook of the API sector has been provided. A future opportunity assessment of every region has also been done to help highlight the areas with promising possibilities.

Excellent growth has been witnessed in pharmaceutical industry in emerging markets. Rising affordability, enhanced life expectancy and improved standard of living are all providing impetus to the demand of pharmaceuticals. However, major regulatory changes in the United States and Europe are set to change the API landscape. As patterns in developed regions continue to remain flat and opportunities for growth shift from traditional markets, the API industry is expected to witness the rise of second wave emerging markets, such as India and China.

As the days of the blockbuster drugs start waning, more flexible manufacturing focused on personalized medicine can be seen as the future of the pharmaceutical business. The report elaborates on the rise of more such trends and challenges, and their possible impacts on the industry.

We have also covered the key players in the Merchant API Market. For every player, a brief business overview, geographical revenue break up, and segment-wise revenue break up has been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global API market.

Table of Contents

1. Analyst View

2. Research Methodology

3. APIs - An Introduction

4. Global API Industry

5. Drivers & Challenges

  • 5.1 Drivers
    • 5.1.1 Rise in Geriatric Population
    • 5.1.2 Increasing Prevalence of Chronic Diseases
    • 5.1.3 Patent Expiry Opening Market for Generic APIs
    • 5.1.4 Asian Markets Offer Considerable Growth Potential
  • 5.2 Challenges
    • 5.2.1 Surging Prices Holding Back Branded Drug Market
    • 5.2.2 Increasingly Challenging Regulatory Environment
    • 5.2.3 Lengthy Product Approval Process
    • 5.2.4 Lack of Transparency in Supply Chain

6. Market Segmentation

  • 6.1 By Type of Manufacturing
    • 6.1.1 Captive Market
    • 6.1.2 Merchant Market
  • 6.2 By Type of Drug
    • 6.2.1 Generic Drug API
    • 6.2.2 Branded Drug API
  • 6.3 By Type of API
    • 6.3.1 Chemical/Small Molecule API
    • 6.3.2 Biotech API
  • 6.4 By Key Geographical Markets
    • 6.4.1 North America
    • 6.4.2 Asia-Pacific
    • 6.4.3 Europe
    • 6.4.4 Rest of the World
  • 6.5 By Therapeutic Segments
    • 6.5.1 Cardiovascular Diseases
    • 6.5.2 Diabetes
    • 6.5.3 Central Nervous System Disorders
    • 6.5.4 Oncology
    • 6.5.5 Others

7. Trends and Developments

  • 7.1 Nanocrystals of APIs to Improve Solubility
  • 7.2 Technological Advancements Aiding API Production

8. Competitive Landscape

  • 8.1 BASF SE
  • 8.2 Kyowa Hakko Kirin
  • 8.3 Teva Active Pharmaceuticals Ingredients
  • 8.4 Lonza
  • 8.5 Dr. Reddy's Laboratories
  • 8.6 Aurobindo Pharma Limited
  • 8.7 Pfizer
  • 8.8 Divis Laboratories Limited
  • 8.9 Royal DSM
  • 8.10 Boehringer Ingelheim GmbH

List of Figures:

  • Figure 4-1: Global - API Market (Billion US$), 2014-2020
  • Figure 5-1: Worldwide Population above 60 Years (Billion), 2014 & 2050
  • Figure 5-2: US - Population Suffering from Chronic Condition (Million), 2014 & 2020
  • Figure 6-1: Global - Share of Captive and Merchant Market in API Market (2014)
  • Figure 6-2: Global - API Captive Market (Billion US$), 2014-2020
  • Figure 6-3: Global - API Merchant Market (Billion US$), 2014-2020
  • Figure 6-4: Global - Share of Branded and Generic Market in API Market (2014)
  • Figure 6-5: Global - Generic API Market (Billion US$), 2014-2020
  • Figure 6-6: Global - Branded API Market (Billion US$), 2014-2020
  • Figure 6-7: Global - Share of Synthetic and Biotech APIs in API Market (2014)
  • Figure 6-8: Global - Chemical/Small Molecule API Market (Billion US$), 2014-2020
  • Figure 6-9: Global - Biotech API Market (Billion US$), 2014-2020
  • Figure 6-10: North America - API Market (Billion US$), 2014-2020
  • Figure 6-11: Asia-Pacific - API Market (US$ Billion), 2014-2020
  • Figure 6-12: Europe - API Market (Billion US$), 2014-2020
  • Figure 6-13: ROW - API Market (Billion US$), 2014-2020
  • Figure 6-14: Breakup of Global API Market by Therapeutic Segments (%), 2014
  • Figure 8-1: BASF SE - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-2: Kyowa Hakko Kirin - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-3: Teva Pharmaceutical Industries Limited - Break up of Revenue by Geographical Segment (%), 2014
  • Figure 8-4: Lonza - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-5: Dr. Reddy's Laboratories - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-6: Aurobindo Pharma Limited - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-7: Pfizer - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-8: Divis Laboratories Limited - Break up of Revenue by Geographic Segment (%), 2014
  • Figure 8-9: Royal DSM - Break up of Revenue by Geographic Origin (%), 2014
  • Figure 8-10: Boehringer Ingelheim GmbH - Break up of Revenue by Geographic Segment (%), 2014

List of Tables:

  • Table 3-1: Classification of Bulk Drugs
  • Table 5-1: Blockbuster Drugs Going Off Patent (2014-2015)
  • Table 8-1: BASF SE - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-2: Kyowa Hakko Kirin - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-3: Teva Pharmaceutical Industries Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-4: Lonza - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-5: Dr. Reddy's Laboratories - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-6: Aurobindo Pharma Limited - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-7: Pfizer - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-8: Divis Laboratories Limited - Revenues (Billion US$), 2013 & 2014
  • Table 8-9: Royal DSM - Revenues by Business Segment (Billion US$), 2013 & 2014
  • Table 8-10: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
Back to Top